SAN DIEGO, April 21, 2015 /PRNewswire/ -- Edico Genome today announced a collaboration with Intel Corporation to develop solutions with Intel's Xeon processors to accelerate next generation sequencing (NGS) data analysis. The resulting solution will enable completion of primary and secondary NGS analysis in real time, while sustaining superior accuracy, decreasing costs, streamlining data analysis in the cloud and holds benefits for applications that require sharing of big data sets, such as analysis of population-scale genomic data.
"Edico Genome's DRAGEN™, the world's first Bio-IT processor, is currently helping clinicians and researchers overcome a key bottleneck in NGS workflow by rapidly analyzing big data, and we look forward to working with Intel to offer a powerful genomics analysis solution," said Pieter van Rooyen, Ph.D., Chief Executive Officer of Edico Genome. "In addition, this partnership accelerates deployment of DRAGEN to Intel's customer base around the world, greatly expanding the reach and adoption of our bioinformatics processor."
"Across industries, the demands of big data are pushing the limits of general purpose processing, creating an opportunity for optimized solutions that are able to keep up with specific data processing demands. As the use of NGS grows, many of our customers, including hospitals and research institutions, have a need for solutions that can process and analyze these huge data sets rapidly and cost effectively," added Ketan Paranjape, General Manager Life Sciences, Intel. "Edico Genome's significant domain expertise in the arena of genomics analysis makes them an ideal partner in this vertical space."
The Edico-Intel collaboration aims to accelerate NGS data analysis in order to meet the challenges of clinical genomics as well as biomedical research, an ongoing focus for Intel. Last year, Intel and the Broad Institute partnered to optimize the frequently used genomics analysis pipeline, Broad's Genome Analysis Toolkit (GATK), for Intel Xeon-powered servers, and together they were able to reduce the time it takes to analyze a whole human genome from three days down to one day. Combined, Edico and Intel technologies are able to analyze a whole genome in approximately 20 minutes.
Mr. Paranjape, Dr. van Rooyen and other bioinformatics pioneers will be participating in a breakfast panel at the Bio-IT World Conference & Expo '15 discussing the challenges of big data in the post-$1,000 genome world and bioinformatics' role in helping to achieve the vision of precision medicine. This will take place on Thursday, April 23 at 7 a.m. ET, and more information can be found on the conference agenda, accessed here: http://www.bio-itworldexpo.com/Bio-It_Expo_Content.aspx?id=143066&libID=143038.
About the DRAGEN Bio-IT Processor
DRAGEN™, the world's first next-generation sequencing (NGS) Bio-IT processor, is a reconfigurable platform designed to massively accelerate secondary analysis of NGS while simultaneously improving accuracy, removing a key bottleneck in NGS workflow. DRAGEN is loaded with highly optimized algorithms for mapping, alignment, sorting and variant calling, and the flexible platform can be loaded with additional algorithms for a range of secondary analysis pipelines, such as whole genome or exome, RNAseq, methylome, microbiome and cancer. The solution can be integrated directly into NGS bioinformatics servers and sequencing instruments and is provided with accompanying software as a Platform-as-a-Service (PaaS). Interested parties may inquire about DRAGEN at http://www.edicogenome.com/dragen/get-dragen-now/.
About Edico Genome
Edico Genome, developer of the world's first next-generation sequencing Bio-IT processor, DRAGEN™, is helping usher in the new era of precision medicine by enabling customized treatments and data-driven insights tailored to the individual. At the heart of personalized medicine is next-generation sequencing (NGS), which is growing at an unprecedented pace. By increasing the speed and accuracy of NGS data analysis, such as whole genome sequencing, Edico Genome's computing platform makes it easier to discover links between DNA sequence variations and human disease, allowing clinicians and researchers to reveal answers more quickly. For more information, visit www.EdicoGenome.com and follow #DRAGENonFIRE.
Senior Director of Marketing
Monica May for Edico Genome
SOURCE Edico Genome